Until the recent FDA approval of Syfovre, there was no treatment to address the symptoms of AMD, according to a May 10 press release.
Syfovre slows degeneration of the retinal cells and provides patients with visual function for many more months or years.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.